|
| | 13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2 Basic information |
| Product Name: | 13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2 | | Synonyms: | 9,15-DIOXO-11ALPHA-HYDROXY-PROST-5Z-EN-1-OIC ACID;15-keto-13,14-dihydroprostaglandine2;13,14-dihydro-15-oxo-prostaglandin E2;CUJMXIQZWPZMNQ-XYYGWQPLSA-N;13,14-dihydro-15-keto Prostaglandin E2 MaxSpecStandard;13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2;(E)-7-[(1R,2R,3R)-3-hydroxy-5-oxo-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid;13,14-Dihydro-15-keto-PGE2 | | CAS: | 363-23-5 | | MF: | C20H32O5 | | MW: | 352.47 | | EINECS: | | | Product Categories: | | | Mol File: | 363-23-5.mol |  |
| | 13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2 Chemical Properties |
| Boiling point | 538.1±45.0 °C(Predicted) | | density | 1.086±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | pka | 4.75±0.10(Predicted) |
| | 13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2 Usage And Synthesis |
| Description | 13,14-dihydro-15-keto Prostaglandin E2 (13,14-dihydro-15-keto PGE2) is a metabolite of PGE2 and the primary PGE2 metabolite in plasma. It is formed from PGE2 via a 15-keto PGE2 intermediate by 15-oxo-PG Δ13 reductase. Unlike PGE2, 13,14-dihydro-15-keto PGE2 does not bind effectively to the PGE2 receptors EP2 and EP4 expressed in CHO cells (Kis = 12 and 57 μM, respectively) or induce adenylate cyclase activity in the same cells (EC50s = >18 and >38 μM, respectively). Levels of 13,14-dihydro-15-keto PGE2 are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery. Levels of 13,14-dihydro-15-keto PGE2 levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC). | | Uses | 13,14-Dihydro-15-ketoPGE2 is a primary metabolite of PGE2 in plasma. | | Definition | ChEBI: The 13,14-dihydro derivative of 15-oxo-prostaglandin E2. |
| | 13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2 Preparation Products And Raw materials |
|
